News & Updates
Filter by Specialty:
Rectal spacer relieves GI issues following RT for prostate cancer
In a large retrospective study, the incidence of bowel disorders and related procedures dropped when a polyethylene glycol-based hydrogel spacer (PHS) was used in men undergoing radiotherapy (RT) for prostate cancer.
Rectal spacer relieves GI issues following RT for prostate cancer
08 May 2025
KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo
First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.
KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo
07 May 2025
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).
